MEBENDAZOLE and Thyroid Cancer - Inhibits tumor growth and prevents lung metastasis

NEW ARTICLE: MEBENDAZOLE and Thyroid Cancer - Inhibits tumor growth and prevents lung metastasis - shocking new Johns Hopkins research on Fenbendazole's sister drug

In a 2020 paper by Johns Hopkins researchers led by Tara Williamson, Mebendazole halted Anaplastic Thyroid Cancer and shrunk Papillary thyroid tumors.

For those of you who know, Anaplastic Thyroid Cancer is one of the most aggressive cancers that exist.

"The purpose of this study was to determine if mebendazole could be repurposed to effectively treat thyroid cancer, in particular before metastasis."

"In vitro, mebendazole potently inhibited the growth of a panel of human papillary and anaplastic thyroid cancer cells"

"In aggressive anaplastic thyroid cancer cells, mebendazole significantly repressed migratory and invasive potential"

"In vivo, mebendazole treatment resulted in significant papillary thyroid tumor regression and growth arrest of anaplastic tumors, with treated tumors displaying reduced expression of the proliferation marker Ki67 and less vascular epithelium"

"Most importantly, daily oral mebendazole prevented established thyroid tumors from metastasizing to the lung"

"Given the low toxicity, this novel preclinical study of mebendazole has promising therapeutic implications for patients with treatment refractory papillary or anaplastic thyroid cancer."

As I continue to do Cancer Consultations, I've been approached by a number of Thyroid Cancer patients who have run out of options.

Seeing the tumors shrink in mice like this is something you don't see everyday and is shocking and impressive.

While Fenbendazole and Ivermectin get all the glory for being the top repurposed drugs for Cancer today (including COVID-19 mRNA Vaccine Induced Turbo Cancers)

it's important to remember that Fenbendazole's sister drug Mebendazole also has a vast body of preclinical research that is, in many cases (including this one), absolutely stunning.

















Tweet